Genital Diseases, Female  >>  Torisel (temsirolimus)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Torisel (temsirolimus) / Pfizer
NCT00659568: Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma

Completed
1
28
Canada
metformin hydrochloride, temsirolimus
London Health Sciences Centre
Breast Cancer, Endometrial Cancer, Kidney Cancer, Lung Cancer, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
02/10
08/10
NCT00408655: Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Tumors

Completed
1
38
Canada
paclitaxel, Anzatax, Asotax, TAX, Taxol, carboplatin, Carboplat, CBDCA, JM-8, Paraplat, Paraplatin, temsirolimus, CCI-779, cell cycle inhibitor 779, Torisel
National Cancer Institute (NCI)
Ovarian Sarcoma, Ovarian Stromal Cancer, Recurrent Endometrial Carcinoma, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Stage III Endometrial Carcinoma, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage IV Endometrial Carcinoma, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific
01/12
 
NCT01155258: Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors

Completed
1
19
US
temsirolimus, CCI-779, cell cycle inhibitor 779, rapamycin analog CCI-779, Torisel, vinorelbine ditartrate, Biovelbin, Eunades, navelbine ditartrate, NVB, vinorelbine tartrate, VNB
University of Southern California, Wyeth is now a wholly owned subsidiary of Pfizer
Extensive Stage Small Cell Lung Cancer, Hereditary Paraganglioma, Male Breast Cancer, Malignant Paraganglioma, Metastatic Gastrointestinal Carcinoid Tumor, Metastatic Pheochromocytoma, Pancreatic Polypeptide Tumor, Recurrent Breast Cancer, Recurrent Cervical Cancer, Recurrent Endometrial Carcinoma, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma, Recurrent Neuroendocrine Carcinoma of the Skin, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Pheochromocytoma, Recurrent Prostate Cancer, Recurrent Renal Cell Cancer, Recurrent Small Cell Lung Cancer, Recurrent Uterine Sarcoma, Regional Gastrointestinal Carcinoid Tumor, Regional Pheochromocytoma, Stage III Cervical Cancer, Stage III Endometrial Carcinoma, Stage III Neuroendocrine Carcinoma of the Skin, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage III Prostate Cancer, Stage III Renal Cell Cancer, Stage III Uterine Sarcoma, Stage IIIA Breast Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Breast Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Endometrial Carcinoma, Stage IV Neuroendocrine Carcinoma of the Skin, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Prostate Cancer, Stage IV Renal Cell Cancer, Stage IV Uterine Sarcoma, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer, Thyroid Gland Medullary Carcinoma
01/13
05/14
NCT01198184: Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors

Checkmark +temsirolimus
Jul 2013 - Jul 2013: +temsirolimus
Checkmark P1 data- ESMO 2012
Sep 2012 - Sep 2012: P1 data- ESMO 2012
Completed
1
18
Canada
temsirolimus, CCI-779, cell cycle inhibitor 779, Torisel, gamma-secretase/Notch signalling pathway inhibitor RO4929097, R4733, RO4929097, laboratory biomarker analysis, pharmacological study, pharmacological studies
National Cancer Institute (NCI)
Endometrial Papillary Serous Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Renal Cell Cancer, Stage III Endometrial Carcinoma, Stage III Renal Cell Cancer, Stage IV Endometrial Carcinoma, Stage IV Renal Cell Cancer, Unspecified Adult Solid Tumor, Protocol Specific
07/13
10/13

Download Options